Sponsor or institution
Clinical trials and research at Xuzhou Medical University
As of November 12, 2026, Find a Trial lists 5 clinical trials run by Xuzhou Medical University that are recruiting, in China. By phase: Phase 1/2 (5). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 1Country
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Treatment for relapsed and refractory multiple myeloma using CAR-T cell therapy | Phase 1/2 | Xuzhou | Recruiting | Jan 6, 2025 |
| Using Iguratimod to treat chronic graft-versus-host disease | Phase 1/2 | Xuzhou, Jiangsu | Recruiting | Feb 6, 2024 |
| Using Anti-FcRL5 CAR-T Cell Therapy for Relapsed Multiple Myeloma | Phase 1/2 | Xuzhou, Jiangsu | Recruiting | Jan 9, 2024 |
| Evaluating a new CAR-T therapy for relapsed multiple myeloma | Phase 1/2 | Xuzhou, Jiangsu | Recruiting | Nov 15, 2023 |
| Using CAR-T cell therapy targeting Tim-3 and CD123 for treating relapsed acute myeloid leukemia | Phase 1/2 | Xuzhou, Jiangsu | Recruiting | Nov 9, 2023 |
All recruiting trials (5)
-
Treatment for relapsed and refractory multiple myeloma using CAR-T cell therapy
This study is testing a new CAR-T cell therapy for people with relapsed and hard-to-treat multiple myeloma to see if it is safe and effective.
-
Using Iguratimod to treat chronic graft-versus-host disease
This study is testing if Iguratimod, a medication usually for rheumatoid arthritis, can help people with chronic graft-versus-host disease feel better and improve their lung function.
-
Using Anti-FcRL5 CAR-T Cell Therapy for Relapsed Multiple Myeloma
This study is testing a new CAR-T cell therapy to see if it can help people with relapsed multiple myeloma feel better and improve their treatment options.
-
Evaluating a new CAR-T therapy for relapsed multiple myeloma
This study is testing a new CAR-T therapy to see if it can help people with relapsed multiple myeloma feel better and improve their treatment outcomes.
-
Using CAR-T cell therapy targeting Tim-3 and CD123 for treating relapsed acute myeloid leukemia
This study is testing a new CAR-T cell therapy that targets specific markers in people aged 18-70 with relapsed acute myeloid leukemia to see if it can safely improve their treatment outcomes.
Quick answers
How many clinical trials run by Xuzhou Medical University are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 5. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.